DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) had its target price trimmed by Craig Hallum from $11.00 to $8.00 in a research note published on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. Separately, Oppenheimer reiterated an outperform rating and issued a $6.00 price objective (down previously from $7.00) on […]
DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy
.
Pfizer s migraine market chief joins Apnimed—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
DiaMedica Therapeutics Inc (DMAC) Appoints Lorianne Masuoka as Chief Medical Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.